Diabetics who've contracted COVID-19 should suspend their use of a class of common diabetes drugs known as sodium-glucose co-transporter 2 inhibitors (SGLT2i), new research warns. People using these medications for diabetes are at risk of a potentially fatal complication called diabetic ketoacidosis (DKA), and it now appears that risk increases even more if they become sick with COVID-19, said senior researcher …